Navigation Links
Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen & Co. 31st Annual Health Care Conference in Boston.

The live presentation takes place on Wednesday, March 9, 2011 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
3. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
4. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
5. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
7. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
10. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
11. Neurocrine Biosciences Amends Corporate Headquarters Lease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say they ... may be hampering the research that could lead to one good one. Surviving Mesothelioma ... it now. , The team evaluated 98 mesothelioma patients who got ...
(Date:5/25/2016)... Haven, Connecticut (PRWEB) , ... May 25, 2016 ... ... that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan ... is the company’s second orphan drug designation granted by the FDA. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an ... and entrepreneurs, held The Future of San Diego Life Science event at the Estancia ... science community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):